OncBioMune Pharmaceuticals announced a partnership with Gem Pharmaceuticals to develop Gem’s proprietary GPX-150 compound for markets in Mexico and Latin America.
OncBioMune Pharmaceuticals (OTCQB:OBMP) announced a partnership with Gem Pharmaceuticals to develop Gem’s proprietary GPX-150 compound in the markets in Mexico and Latin America.
As quoted in the press release:
Built upon Gem’s proprietary non-cardiotoxic anthracycline technology, GPX-150 (5-imino-13-deoxydoxorubicin) is being developed by Gem for several hard-to-treat diseases and conditions. Gem has successfully completed a Phase 2 trial in the United States that met safety goals and demonstrated a therapeutic benefit in adult patients with metastatic and nonresectable soft tissue sarcoma (STS). Gem believes GPX-150 may have the potential to be an important component of first-line therapy due to an improved safety and tolerability profile compared to doxorubicin, a standard of care today for STS.
“GPX-150 is a novel anthracycline compound that current research shows can deliver a meaningful therapeutic benefit without causing cardiotoxicity, the biggest issue with doxorubicin, which potentially represents a huge leap forward in cancer care,” commented Jonathan Head, Ph.D., Chief Executive Officer at OncBioMune. “The Gem team has done a fine job so far in advancing GPX-150. We greatly look forward to working with them on what is an excellent opportunity to explore a large market across MALA.”
The execution of an agreement is subject to customary terms and conditions, including a definitive agreement between OncBioMune and Gem. While both parties are moving forward in good faith to complete a definitive agreement, no guarantees are expressed or implied.
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About Gem Pharmaceuticals
Gem Pharmaceuticals is a privately owned, clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specifically designed to eliminate the critical irreversible cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy. In so doing, Gem seeks to transform traditional broad-spectrum cytotoxic drugs into modern — and biochemically targeted — anti-cancer agents that hold the potential for higher and/or longer-term dosing and correspondingly improved therapeutic utility. Gem believes that its lead non-cardiotoxic anthracycline compound (GPX-150) has the potential to attain significant market penetration by replacing the existing use of doxorubicin and other anthracyclines; by expanding the oncology uses of anthracyclines; and by broadening anthracycline use beyond cancer. For additional information about Gem, please visit www.gempharmaceuticals.com.